[Skip to Content]
[Skip to Content Landing]
Article
December 15, 1989

Benzodiazepines of Long and Short Elimination Half-life and the Risk of Hip Fracture

Author Affiliations

From the Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, Tenn (Drs Ray and Griffin); and the Laboratory and Disease Control Services Branch, Saskatchewan Health, Regina, Canada (Ms Downey).

From the Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, Tenn (Drs Ray and Griffin); and the Laboratory and Disease Control Services Branch, Saskatchewan Health, Regina, Canada (Ms Downey).

JAMA. 1989;262(23):3303-3307. doi:10.1001/jama.1989.03430230088031
Abstract

To determine if the risk of hip fracture differed between persons receiving benzodiazepines with long (≥24 hours) or short (<24 hours) elimination half-lives, we conducted a nested case-control study among residents of the Canadian province of Saskatchewan who were 65 years of age and older. We identified 4501 cases occurring between 1977 and 1985 from computerized hospital records and 24 041 population controls. Current benzodiazepine use, defined as having filled a prescription in the past 30 days, was ascertained from computerized pharmacy records. The relative risk of hip fracture was 1.7 (95% confidence interval, 1.5 to 2.0) for current users of long half-life benzodiazepines, in contrast to that of 1.1 (95% confidence interval, 0.9 to 1.3) for current users of short half-life drugs. This finding was not altered by sex, age, calendar year, nursing home residence, or history of hospitalization. Medical record review for a sample of 189 cases suggested that this finding was not due to confounding by dementia, ambulatory status, functional status, or body mass.

(JAMA. 1989;262:3303-3307)

×